Angiotensin II and Cellular Senescence: Mechanistic Insights for Abdominal Aortic Aneurysm Models

Introduction

Abdominal aortic aneurysm (AAA) represents a critical vascular pathology characterized by progressive dilation of the abdominal aorta, often remaining clinically silent until rupture. The molecular mechanisms underlying AAA progression involve complex interactions between vascular wall remodeling, inflammation, and cellular senescence. Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), an endogenous octapeptide hormone and a potent vasopressor and GPCR agonist, has emerged as a pivotal experimental tool in dissecting these processes. By activating angiotensin receptor signaling pathways and triggering downstream effectors such as phospholipase C activation and IP3-dependent calcium release, Angiotensin II is central to vascular smooth muscle cell hypertrophy research, hypertension mechanism study, and cardiovascular remodeling investigation.

Angiotensin II: Structure, Biochemical Properties, and Mechanisms of Action

Angiotensin II (CAS 4474-91-3), with the amino acid sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, is synthesized from angiotensin I via angiotensin-converting enzyme (ACE) activity. It exerts its effects primarily by binding with high affinity (IC₅₀: 1–10 nM, assay-dependent) to angiotensin type 1 (AT1) and type 2 (AT2) receptors—members of the G protein-coupled receptor (GPCR) family—on vascular smooth muscle and adrenal cortical cells. Upon receptor engagement, Angiotensin II induces a cascade involving phospholipase C activation, generation of inositol trisphosphate (IP3), subsequent intracellular calcium release, and activation of protein kinase C.

These signaling events mediate rapid vasoconstriction and promote aldosterone secretion, which in turn facilitates renal sodium and water reabsorption. Together, these mechanisms play indispensable roles in the regulation of systemic blood pressure and extracellular fluid balance. Notably, Angiotensin II’s solubility profile (≥234.6 mg/mL in DMSO, ≥76.6 mg/mL in water, insoluble in ethanol) and stability when stored in sterile water at -80°C render it highly suitable for both in vitro and in vivo experimental paradigms. For further details on preparation and biophysical characteristics, see the Angiotensin II product page.

Cellular Senescence and Vascular Remodeling: A Convergence in AAA Pathogenesis

Emerging evidence implicates cellular senescence—the stable cell-cycle arrest accompanied by a senescence-associated secretory phenotype (SASP)—as a key driver of vascular aging and aneurysm formation. In the context of AAA, senescent endothelial and smooth muscle cells contribute to chronic inflammation, extracellular matrix degradation, and maladaptive vascular remodeling. These processes are exacerbated by hemodynamic stressors and neurohormonal modulators, notably Angiotensin II.

In experimental models, Angiotensin II infusion (e.g., 500–1000 ng/min/kg in C57BL/6J apoE–/– mice for 28 days) robustly induces AAA formation, characterized by marked vascular remodeling, medial degeneration, and adventitial inflammation. Mechanistically, Angiotensin II triggers the activation of NADH and NADPH oxidases in vascular smooth muscle cells (VSMCs), resulting in elevated reactive oxygen species (ROS) production and DNA damage—hallmarks of senescence induction. Moreover, Angiotensin II promotes inflammatory cell infiltration and upregulation of matrix metalloproteinases, further destabilizing the vessel wall and fostering aneurysm expansion.

Senescence-Related Biomarkers in AAA: Insights from Transcriptomic and Machine Learning Approaches

The identification of reliable molecular biomarkers for AAA has been historically challenging due to the disease’s insidious onset and anatomical heterogeneity. A recent study by Zhang et al. (Journal of Cellular and Molecular Medicine, 2025) employed a multi-omics approach, integrating transcriptomic profiling with machine learning algorithms, to elucidate the role of cellular senescence in AAA pathogenesis. In this work, 429 differentially expressed genes (DEGs) and 867 senescence-related genes (SRGs) were systematically analyzed, yielding 19 differentially expressed senescence-related genes (DESRGs) implicated in AAA.

The authors applied LASSO, SVM-Recursive Feature Elimination, and random forest classifiers to prioritize hub genes, which were subsequently validated in independent human and murine cohorts. Notably, ETS1 and ITPR3 emerged as robust diagnostic signatures, with significant upregulation in AAA tissues and strong discriminatory power in receiver operating characteristic (ROC) analyses. Functional validation using single-cell RNA sequencing, western blotting, and immunofluorescence staining confirmed the association between these senescence markers and AAA progression, particularly in senescent endothelial cells.

Mechanistic Intersection: Angiotensin II, ITPR3, and Vascular Senescence

A novel aspect highlighted by the Zhang et al. study is the mechanistic link between Angiotensin II-induced signaling and the regulation of ITPR3 (inositol 1,4,5-trisphosphate receptor type 3). ITPR3 functions as a critical mediator of IP3-dependent calcium release from the endoplasmic reticulum, a process directly downstream of angiotensin receptor activation. By stimulating phospholipase C and increasing intracellular IP3, Angiotensin II facilitates calcium mobilization through ITPR3, thereby influencing contractile responses, VSMC hypertrophy, and potentially senescence induction.

These findings suggest that experimental modulation of ITPR3 expression or function—using Angiotensin II as a tool—may provide new avenues for dissecting the interplay between GPCR-mediated calcium signaling, oxidative stress, and vascular cell senescence. This approach is particularly relevant for models of AAA and other forms of vascular injury, where inflammatory responses and maladaptive remodeling are prominent.

Practical Guidance for Experimental Design: Leveraging Angiotensin II in AAA and Senescence Research

For researchers aiming to interrogate the mechanistic basis of AAA or vascular senescence, Angiotensin II offers a reproducible and physiologically relevant stimulus. In vitro, treatment of VSMCs with 100 nM Angiotensin II for 4 hours has been shown to increase NADH/NADPH oxidase activity and ROS production, recapitulating aspects of oxidative stress and cellular aging. In vivo, subcutaneous minipump infusion in genetically susceptible mouse strains (e.g., apoE–/– or LDLR–/–) reliably induces aneurysmal changes, allowing for temporal analysis of senescence markers, inflammatory mediators, and vascular remodeling.

To maximize experimental rigor, investigators should consider the following:

• Confirm peptide solubility and stability in sterile water prior to use; prepare aliquots to minimize freeze-thaw cycles.
• Utilize appropriate controls, including saline-infused or vehicle-treated animals, to delineate Angiotensin II-specific effects.
• Employ multi-modal readouts (histopathology, RNA/protein expression, oxidative stress assays) to capture the spectrum of Angiotensin II-induced changes.
• Integrate senescence-specific endpoints, such as p16^INK4a, β-galactosidase activity, ETS1, and ITPR3 quantification, to connect molecular signaling to functional vascular outcomes.

Such strategies enable a comprehensive evaluation of the angiotensin receptor signaling pathway in AAA and vascular senescence models, facilitating translational insights for biomarker discovery and therapeutic intervention.

Emerging Directions: Targeting Senescence Pathways for AAA Therapy

The identification of ETS1 and ITPR3 as senescence-related diagnostic markers opens new possibilities for targeted intervention. Modulating Angiotensin II-induced calcium signaling or inhibiting downstream oxidative stress pathways may attenuate the deleterious effects of vascular senescence in AAA. Furthermore, integrating high-throughput transcriptomic and proteomic profiling with classical pharmacological models (using Angiotensin II) could accelerate the discovery of druggable targets within the angiotensin receptor signaling axis.

These advances underscore the importance of combining mechanistic studies of GPCR agonists like Angiotensin II with biomarker-driven approaches, as exemplified in the recent literature. For an in-depth discussion on Angiotensin II-induced VSMC hypertrophy, readers may reference the article Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy....

Conclusion

Angiotensin II remains an indispensable reagent for cardiovascular remodeling investigation, abdominal aortic aneurysm modeling, and vascular injury inflammatory response research. Its capacity to orchestrate complex signaling cascades—encompassing phospholipase C activation, IP3-dependent calcium release, and aldosterone-mediated sodium reabsorption—renders it uniquely suited for probing the pathophysiological nexus between hypertension, vascular remodeling, and cellular senescence. The integration of Angiotensin II-based models with advanced molecular diagnostics, particularly the assessment of senescence-related biomarkers such as ETS1 and ITPR3, promises to refine our understanding of AAA and inform innovative therapeutic strategies.

While prior articles—such as Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy...—have focused on hypertrophic responses and general GPCR signaling, the present article uniquely delineates the intersection of Angiotensin II signaling with cellular senescence pathways in AAA. By explicitly integrating recent multi-omics findings and providing practical guidance for leveraging Angiotensin II in senescence biomarker research, this work extends the current scientific discourse and highlights novel opportunities for translational investigation in vascular disease models.